Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H1 2016

Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H1 2016
Published Jun 28, 2016
54 pages — Published Jun 28, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H1 2016, provides in depth analysis on Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted pipeline therapeutics.

The report provides comprehensive information on the Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5)
- The report reviews Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics and enlists all their major and minor projects
- The report assesses Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- Th

  
Source:
Document ID
GMDHC0137TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Overview71
Therapeutics Development83
  Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Products under Development by Stage of Development81
  Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Products under Development by Therapy Area91
  Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Products under Development by Indication101
Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Pipeline Products Glance112
  Late Stage Products111
  Early Stage Products121
Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Products under Development by Companies132
Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Products under Development by Universities/Institutes152
Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Therapeutics Assessment174
  Assessment by Monotherapy/Combination Products171
  Assessment by Route of Administration181
  Assessment by Molecule Type192
Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Companies Involved in Therapeutics Development216
  Advaxis, Inc.211
  Akshaya Bio Inc.221
  Celgene Corporation231
  Etubics Corporation241
  OSE Immunotherapeutics251
  Vaxon Biotech261
Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Drug Profiles2714
  ETBX-011 Drug Profile273
  GI-6207 Drug Profile302
  OSE-2101 Drug Profile323
  Peptides to Activate CEACAM5 for Crohn's Disease Drug Profile351
  Vaccine to Target CEA for Oncology Drug Profile361
  Vaccine to Target CEA for Ovarian Cancer Drug Profile372
  Vbx-016 Drug Profile391
  Vbx-026 Drug Profile401
Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Dormant Projects411
Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Discontinued Products421
Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Featured News &Press Releases4310
  Feb 22, 2016: First patients enrolled and dosed in the pivotal trial of Phase 3 of the immunotherapy Tedopi for advanced non-small cell lung cancer431
  Feb 04, 2016: OSE Pharma Announces U.S. Initiation of Atalante 1, the Company s Global, Pivotal Phase 3 Trial for Tedopi Immunotherapy in Non-Small Cell Lung Cancer431
  Jan 06, 2016: OSE Pharma Announces Initiation of Its Pivotal Phase 3 Trial of Tedopi in Non-Small Cell Lung Cancer441
  Sep 29, 2015: OSE Pharma to participate to the Large &Midcap Event in Paris on October 7-8, 2015451
  Aug 05, 2015: Etubics Platform Shown to Significantly Increase Survival Of End Stage Colorectal Cancer Patients451
  Jun 22, 2015: Vaxon Biotech granted Japanese patent for new cancer vaccine candidates461
  May 28, 2015: OSE Pharma and Simbec- Orion to participate in the 51st annual Meeting of the American Society of Clinical Oncology, May 29th to June 2nd 2015, Chicago471
  Jan 29, 2015: OSE Pharma appoints Simbec-Orion to conduct its Tedopi Phase III international clinical trial in advanced lung cancer patients471
  Sep 15, 2014: Texopi, a new ray of hope for lung cancer immunotherapy481
  Jun 23, 2014: Agreement on Phase 3 Trial Protocol of OSE Pharma's OSE-2101 From the FDA and EMA491
  May 28, 2014: Etubics Will Present Results of Its Colorectal Cancer Phase 1 and 2 Immunotherapy Trial at the Annual American Society of Clinical Oncology Meeting in Chicago501
  Jun 04, 2013: OSE Pharma Announces A Grant From OSEO For Its Targeted Cancer Immune Therapy In Phase III501
  May 06, 2013: Etubics Platform Generates Solid Immune Response In Colorectal Cancer Patients511
  Apr 03, 2013: GlobeImmune Initiates Phase II Study Of New T Cell Stimulating Cancer Vaccine Targeting CEA In Patients With Metastatic Medullary Thyroid Cancer521
  Feb 14, 2013: OSE Pharma Announces The Orphan Drug Status Granted In The US For OSE 2101521
Appendix532
  Methodology531
  Coverage531
  Secondary Research531
  Primary Research531
  Expert Panel Validation531
  Contact Us531
  Disclaimer541

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H1 2016" Jun 28, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Carcinoembryonic-Antigen-Related-Cell-Adhesion-Molecule-5-Carcinoembryonic-Antigen-or-CEA-or-Meconium-Antigen-100-or-CD66e-or-CEACAM5-Pipeline-Review-H1-2016-2088-16041>
  
APA:
Global Markets Direct - Market Research. (2016). Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H1 2016 Jun 28, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Carcinoembryonic-Antigen-Related-Cell-Adhesion-Molecule-5-Carcinoembryonic-Antigen-or-CEA-or-Meconium-Antigen-100-or-CD66e-or-CEACAM5-Pipeline-Review-H1-2016-2088-16041>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.